ImmunityBio Prices 33.3-Million-Share Offering at $3 per Share, Expecting Gross Proceeds of About $100 Million

MT Newswires Live12-11

ImmunityBio (IBRX) said Wednesday it priced a public offering of 33.3 million shares at $3 per share for gross proceeds of about $100 million.

The company has given underwriters a 30-day option to purchase up to an additional 5 million shares at the offering price, minus underwriting discounts and commissions.

Proceeds from the offering, scheduled to close Thursday, are intended to fund continued commercialization of Anktiva for treating BCG-unresponsive non-muscle invasive bladder cancer, including carcinoma in situ with or without papillary tumors, and to support trials for BCG-naive NMIBC and non-small cell lung cancer, research and development, working capital needs, and other general corporate purposes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment